Search results for: Institute for Clinical and Economic Review (ICER)
Filter search results
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the National Institute of Health…
Hareth Al-Janabi
3 February 2023
…health promotion in schools and workplaces. Hareth’s research interests include the measurement of wellbeing and preferences, the role of family (informal) care in the economic evaluation and decision-making, the economics…
OHE Annual Lecture 2023 | The ECO-nomics of Health in a Shifting Climate: Fostering Well-being, Sustainable Livelihoods, and a Greener Future
13 September 2023, 6:00pm
…the Grantham Research Institute at the London School of Economics and Political Science, as she delivered our Annual Lecture reframing the economics of health and healthcare in a changing climate….
Dr Koonal Shah
22 November 2023
Koonal is an associate director in the Science Policy and Research team at the National Institute for Health and Care Excellence. His project portfolio includes overseeing the NICE Listens deliberative…
Prof. Elizabeth Robinson
8 March 2024
Prof. Elizabeth Robinson is Director of the Grantham Research Institute on Climate Change and the Environment. Professor Robinson has a background as an Environmental Economist with over 25 years of…
Dr. Matthijs Versteegh
19 March 2024
Dr Versteegh is the Founder and Co-Owner of Huygens & Versteegh, a company for health economic research. Prior to this, he was the Director of the Institute of Medical Technology…
Dr. Jacoline Bouvy
19 March 2024
Dr. Jacoline Bouvy is the Programme Director of Medicines Evaluation at the National Institute for Health and Care Excellence (NICE). She is responsible for the delivery of medicines guidance produced…
OHE Annual Lecture Webinar 2020: How Should the World Pay for a COVID-19 Vaccine?
24 June 2020, 11:00pm
…set out the options for funding development and manufacture for vaccines and their strengths and weaknesses, including what is likely to happen if there is no regional or global collaboration…
In Memoriam: George Teeling Smith, OHE’s First Director
17 February 2013
…pricing agreement had been in place between industry and government since 1957 — then called the “VPRS” and the “V” did not stand for ”value”, but for “voluntary”. The government…